Search results
Apr 19, 2022 · Staphylococcal toxic shock syndrome (TSS) is a clinical illness characterized by rapid onset of fever, rash, hypotension, and multiorgan system involvement. TSS due to Staphylococcus aureus was initially described in 1978; the disease came to public attention in 1980 with the occurrence of a series of menstrual-associated cases [ 1,2 ].
- UpToDate
Staphylococcal toxic shock syndrome (TSS) was originally...
- Invasive group A streptococcal infection and toxic shock ...
Streptococcal toxic shock syndrome - Management of septic...
- UpToDate
Aug 7, 2023 · Toxic shock syndrome (TSS) is an acute-onset illness characterized by fever, hypotension, sunburn-like rash, and end-organ damage. TSS was classically associated with high absorbency tampon use in menstruating women until eventually, these were taken off the market. Since that time, it has become important also to consider non-menstrual cases. The incidence of TSS is estimated to be around 0.8 ...
- Martina Afshar Reiss
- 2000
Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1. Group A streptococcal infections and a toxic shock-like syndrome. N Engl J Med 1989; 321:1545. Martin PR, Høiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988.
People also ask
What is toxic shock syndrome (TSS)?
What are the complications of toxic shock syndrome?
What is Staphylococcal toxic shock syndrome (TSS)?
{{configCtrl2.info.metaDescription}}
UpToDate, electronic clinical resource tool for physicians and patients that provides information on Adult Primary Care and Internal Medicine, Allergy and Immunology, Cardiovascular Medicine, Emergency Medicine, Endocrinology and Diabetes, Family Medicine, Gastroenterology and Hepatology, Hematology, Infectious Diseases, Nephrology and Hypertension, Neurology, Obstetrics, Gynecology, and Women ...
This survival benefit was maintained even in patients without shock or necrotising fasciitis (six [2·6%] of 239 patients treated with adjunctive clindamycin vs 27 [6·1%] of 422 patients not treated with adjunctive clindamycin; aOR 0·40 [0·15-0·91]).
